OABI · OmniAb, Inc. · Stock research

and# OABI — OmniAb, Inc.

Current Thesis

OmniAb licenses antibody- and ion-channel-discovery technology to drug developers and gets paid in upfronts, milestones and single-digit royalties on molecules other companies fund. For three years that model produced almost no revenue; in August 2026 it produced two step-changes in twelve days. Q2 revenue of $13.415M (reported 2026-08-06) came in against a $4.693M consensus, and on 2026-08-17 a global collaboration with Eli Lilly for a new ion-channel program added an undisclosed upfront plus up to $370M of R&D and commercial milestones and tiered royalties. Closes moved $1.96 (2026-08-03) → $3.08 (2026-08-07) → $4.33 (2026-08-21), the last of five consecutive higher closes and a 52-week high with RSI(14) at 97.6. The narrative leg an investor buys here is that milestone revenue has become recurring rather than episodic; the price already discounts a good deal of that, and the next company-scheduled test of it is the Q3 print, not September.

Bullish and bearish views on OmniAb, Inc.

The model's bull view on OmniAb, Inc. (OABI), in brief: Q2 2026 (2026-08-06): revenue $13.415M vs $4.693M consensus and $3.9M in Q2 2025; EPS -$0.05 vs -$0.12 estimate; net loss narrowed to $5.9M from $15.9M a year earlier. The bear view: Mix quality: $9.515M of $13.415M in Q2 was license and milestone revenue, which is event-driven and does not repeat on a schedule. Both cases follow in full.

Bull Case

• Q2 2026 (2026-08-06): revenue $13.415M vs $4.693M consensus and $3.9M in Q2 2025; EPS -$0.05 vs -$0.12 estimate; net loss narrowed to $5.9M from $15.9M a year earlier.
• License and milestone revenue was $9.515M of the Q2 total — the line that had been dormant is now the engine.
• FY2026 revenue guidance raised 2026-08-06 to $32–36M from $28–33M, against a $30.807M consensus figure.
• 2026-08-17: Lilly global collaboration and license for a new ion-channel program — undisclosed upfront, up to $370M in R&D/commercial milestones, tiered royalties. It extends paid validation beyond antibodies into the ion-channel screening franchise.
• Same day, year-end 2026 cash guidance raised to $49–53M from $37–41M, attributed to recent licensing and business-development activity.
• Portfolio KPIs disclosed with Q2 2026: 110 active partners, 425 active programs, 34 clinical-stage or approved, more than 98% of active programs carrying contracted future economics, over $3B of aggregate contracted potential milestones, an average royalty rate of roughly 3.4%, and $340M of remaining contracted potential tied to programs already in the clinic. Eight of the ten largest pharmaceutical companies are partners.
• Funnel events cited in the Q2 business highlights: ramantamig (JNJ-79635322) moving into Phase 3 in multiple myeloma and a Phase 3 initiation for precemtabart tocentecan in metastatic colorectal cancer, with TEV-'408 and IMVT-1402 also progressing. OmniAb funds none of these trials.
• H.C. Wainwright reiterated Buy with an $11 price target on 2026-08-17.

Bear Case

• Mix quality: $9.515M of $13.415M in Q2 was license and milestone revenue, which is event-driven and does not repeat on a schedule. One large deal makes a quarter; the absence of one unmakes the next.
• H1 2026 revenue was $27.8M against a raised full-year guide of $32–36M. Inference, not disclosure: management is not underwriting a second half anywhere near the first, which is consistent with unearned milestones staying out of the guide — and with the Q2 comparison being the hardest one the stock will face.
• The $370M Lilly figure is contingent milestone potential, not booked revenue; the upfront was not disclosed (noted by FierceBiotech on 2026-08-17 as details remaining vague). The market is capitalising a headline whose near-term cash component is unknown to it.
• Still loss-making, with a year-end cash target of $49–53M. A small-cap platform with a ~3.4% average royalty rate and a thin approved-product base is not yet self-funding from royalties.
• Coverage is thin: the $11 target is a single-house anchor (H.C. Wainwright, 2026-08-17), roughly 2.5x the 2026-08-21 close, with no visible competing target in the recent record.
• Nothing company-confirmed is dated between 2026-08-22 and 2026-09-21. A stock 121% above its 2026-08-03 close with RSI(14) at 97.6 has to hold on flow alone until the Q3 print.

Setup & Price Structure

• Daily closes: $1.96 (08-03), $2.00, $2.03, $2.24 (08-06, print day), $3.08 (08-07), then a five-session shelf at $3.38–$3.43 (08-10 through 08-14), then $3.82 (08-17, Lilly), $3.92, $4.19, $4.30, $4.33 (08-21).
• Two discrete event gaps with one consolidation between them. The $3.38–$3.43 shelf is the only well-defined base in the structure and it sits nearly a dollar under the 2026-08-21 close of $4.33.
• The shares are up 63.4% over three months and closed 2026-08-21 exactly at the 52-week high of $4.33, with RSI(14) at 97.6 — a top-percentile momentum reading that has historically preceded either a shallow shelf-building pause or a fast give-back, and which by itself distinguishes neither.
• Life-cycle: ACCELERATING. What dates it: the 2026-08-06 guidance raise, the 2026-08-17 Lilly announcement and cash-guidance revision, retail-facing "stocks moving higher" and health-care premarket-gainer screens including OABI on 2026-08-07 and 2026-08-17, and a fresh 52-week high five sessions after the catalyst. The move is days old, not months old.
• Crowding and positioning observables, stated as observables: five consecutive higher closes into a 52-week high; RSI(14) 97.6 at the 2026-08-21 close; two rounds of gainer-list coverage clustering (08-07, 08-17); the earnings event already behind the stock since 2026-08-06, so no scheduled print underwrites the bid; a single sell-side target ($11) doing the anchoring work. No insider transactions and no registered equity offering appear in the filings record reviewed through 2026-08-21 — an absence in the record, which is not the same as an assurance that issuance into strength will not follow a doubling.

Catalyst Calendar (next 30 days)

• 2026-08-22 → 2026-09-21: no company-confirmed dated event. The investor events page and news feed carried nothing after the 2026-08-17 releases as of the 2026-08-22 check.
• ~2026-09-08 to ~2026-09-10 (est., unconfirmed): H.C. Wainwright Annual Global Investment Conference window. OmniAb participated in that house's royalty-company conference on 2026-05-06 and in the Jefferies Global Healthcare Conference on 2026-06-03; participation this September has not been announced.
• ~2026-11-05 (est.): Q3 2026 results. Q2 was reported 2026-08-06. This is the first scheduled test of whether the license-and-milestone line repeats.

Elapsed catalysts

• Undated, partner-driven, any day: partner milestone announcements. The 2026-07-27 VERAXA Biotech disclosure advancing bispecific ADC VXA-222 on an OmniAb milestone is the template, and the 2026-08-17 Lilly deal shows what one of these does to the tape. (passed 6d ago)

What Would Change Our Mind

The whole August advance rests on one shelf: the five sessions at $3.38–$3.43 between 2026-08-10 and 2026-08-14, which is both the post-earnings base and the launch level for the Lilly gap. Losing it would say the deal move was distribution into retail attention rather than a re-rating — a daily close below $3.38 is the gradeable break. On the business side, the read weakens if the Q3 print (~2026-11-05, est.) arrives without another FY guidance raise, or if the license-and-milestone line reverts toward the sub-$4M quarterly revenue pattern of 2025, because the case rests entirely on that line being recurring. A registered offering priced into the strength would change the arithmetic of the year-end $49–53M cash guide and the reason for it. And if the next three to four weeks pass with no partner headline while price mean-reverts toward the shelf, the theme has aged out of ACCELERATING without anything new to sustain it.

Correlation Notes

• Revenue depends on large-pharma discovery and business-development budgets — Lilly (2026-08-17), a JNJ-coded Phase 3 asset, and 8 of the top 10 pharma as partners — while the equity trades with small-cap biotech risk appetite. Those two drivers are not synchronised.
• Index beta explains none of the re-rating.
• Comparable frame is the biotech royalty/platform cohort (Ligand, from which OmniAb was separated in late 2022; Royalty Pharma; Halozyme) rather than clinical-stage biotech — long-duration milestone and royalty streams, so sensitivity to rate expectations runs through the discount rate on a decade of contingent cash flows.
• Single-name partner risk cuts both ways: one Lilly-scale deal moved the stock from $3.38 to $4.33 in four sessions, and the same concentration means one partner discontinuation can be repriced just as fast.